|Anteo Diagnostics Limited -- Australia Stock|| |
AUD 0.02 0.00 0.00%
Chief Product Development and Research Officer
Dr. Nevin Abernethy Ph.D. is Chief Product Development and Research Officer of Anteo Diagnostics Limited. He was awarded his PhD in animal physiology by the University of Toronto Canada in 1989. After working as a Research Officer and lecturer at the University of Melbournes Department of Veterinary and PreClinical Sciences he moved to Auckland New Zealand where he was a Research Fellow in the Department of Molecular Medicine at the University of Auckland prior to joining Genesis Research and Development Corporationration at the time the biotech company in New Zealand. Nevin is named as an inventor on a number of patents in the area of therapeutics and immunological diseases has published numerous peer reviewed papers in related areas and has demonstrated in product development programs similar to those of interest to BioLayer.
Executive Since 2007
61 7 3219 0085 http://www.anteodx.com
The company has return on total asset (ROA)
of (2.66) %
which means that it has lost $2.66 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (68.77) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 677.27 K in total debt with debt to equity ratio (D/E) of 11.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Anteo Diagnostics Limited has Current Ratio of 1.15 suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due.
Anteo Diagnostics Limited, a medical technology company, develops and commercializes specialized surfaces for use in life sciences industries in Australia. Anteo Diagnostics Limited (ADO) is traded on Australian Securities Exchange in Australia. It is located in Eight Mile Plains, QLD and employs 99 people.